BR0313150A - Gelatin capsules exhibiting reduced cross-linking - Google Patents
Gelatin capsules exhibiting reduced cross-linkingInfo
- Publication number
- BR0313150A BR0313150A BR0313150-5A BR0313150A BR0313150A BR 0313150 A BR0313150 A BR 0313150A BR 0313150 A BR0313150 A BR 0313150A BR 0313150 A BR0313150 A BR 0313150A
- Authority
- BR
- Brazil
- Prior art keywords
- gelatin capsules
- linking
- reduced cross
- exhibiting reduced
- capsules exhibiting
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Rheumatology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
Abstract
"CáPSULAS DE GELATINA QUE EXIBEM LIGAçãO RETICULADA REDUZIDA". A presente invenção refere-se a composições adequadas para utilização de cápsulas de gelatina, a cápsulas de gelatina apresentando ligação reticulada reduzida e a métodos para preparar essas cápsulas de gelatina."GELATINE CAPSULES DISPLAYING REDUCED RETICULATED CONNECTION". The present invention relates to compositions suitable for use of gelatin capsules, to gelatin capsules having reduced cross-linking and to methods for preparing such gelatin capsules.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39986302P | 2002-07-31 | 2002-07-31 | |
US39980802P | 2002-07-31 | 2002-07-31 | |
US39986202P | 2002-07-31 | 2002-07-31 | |
US39977602P | 2002-07-31 | 2002-07-31 | |
PCT/US2003/024045 WO2004010974A2 (en) | 2002-07-31 | 2003-07-31 | Gelatin capsule exhibiting reduced cross-linking |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0313150A true BR0313150A (en) | 2005-06-28 |
Family
ID=31192378
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0313064-9A BR0313064A (en) | 2002-07-31 | 2003-07-31 | Pharmaceutical dosage form comprising a sulfite compound |
BR0312875-0A BR0312875A (en) | 2002-07-31 | 2003-07-31 | Film-Resistant Gelatin Capsule |
BR0313150-5A BR0313150A (en) | 2002-07-31 | 2003-07-31 | Gelatin capsules exhibiting reduced cross-linking |
BR0313149-1A BR0313149A (en) | 2002-07-31 | 2003-07-31 | Pharmaceutical dosage form capable of stable dissolution profile after storage |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0313064-9A BR0313064A (en) | 2002-07-31 | 2003-07-31 | Pharmaceutical dosage form comprising a sulfite compound |
BR0312875-0A BR0312875A (en) | 2002-07-31 | 2003-07-31 | Film-Resistant Gelatin Capsule |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0313149-1A BR0313149A (en) | 2002-07-31 | 2003-07-31 | Pharmaceutical dosage form capable of stable dissolution profile after storage |
Country Status (7)
Country | Link |
---|---|
EP (4) | EP1526847A2 (en) |
JP (4) | JP2006500389A (en) |
AU (4) | AU2003257102A1 (en) |
BR (4) | BR0313064A (en) |
CA (4) | CA2494069A1 (en) |
MX (4) | MXPA05001166A (en) |
WO (4) | WO2004022032A2 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1549299B1 (en) | 2002-06-05 | 2014-08-20 | IVAX Pharmaceuticals s.r.o. | Reduction of gelatin cross-linking |
AU2006214164B2 (en) | 2005-02-17 | 2010-12-09 | Synta Pharmaceuticals Corp. | Isoxazole combretastin derivatives for the treatment of disorders |
US7485323B2 (en) | 2005-05-31 | 2009-02-03 | Gelita Ag | Process for making a low molecular weight gelatine hydrolysate and gelatine hydrolysate compositions |
PL1906938T3 (en) | 2005-07-26 | 2011-05-31 | Nicox Science Ireland | Pharmaceutical formulation of nitrooxyderivatives of nsaids |
JP5503939B2 (en) * | 2009-10-16 | 2014-05-28 | 東洋カプセル株式会社 | Azelastine hydrochloride-containing capsule |
JP6887456B2 (en) | 2018-07-04 | 2021-06-16 | キャプシュゲル・ベルジウム・エヌ・ヴィ | A film-forming composition containing a surfactant or a surfactant and a salt as a whitening agent. |
US11364478B2 (en) * | 2019-05-22 | 2022-06-21 | Mezzimatic, LLC | Method of manufacturing throwable paintballs and paintballs made therefrom |
WO2022119269A1 (en) * | 2020-12-01 | 2022-06-09 | 주식회사 엘지화학 | Stable oral formulation containing 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid |
CN113230241A (en) * | 2021-06-11 | 2021-08-10 | 北京畅盛医药科技有限公司 | Application of tris (hydroxymethyl) aminomethane salt in medicine for treating cardiovascular and cerebrovascular diseases |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5115094B2 (en) * | 1972-11-01 | 1976-05-14 | ||
US4349529A (en) * | 1980-04-14 | 1982-09-14 | E. R. Squibb & Sons, Inc. | Diagnostic and therapeutic capsules and method of producing |
US4590183A (en) * | 1985-04-22 | 1986-05-20 | Sterling Drug Inc. | Gastric cytoprotection with sodium thiosulfate in oral administration of aspirin |
FR2617047B1 (en) * | 1987-06-23 | 1991-05-10 | Sanofi Sa | TANNING RESISTANT GELATIN COMPOSITION, CAPSULES BASED ON THIS COMPOSITION AND THEIR PHARMACEUTICAL APPLICATION, IN PARTICULAR TO FENOFIBRATE |
JP2790659B2 (en) * | 1989-06-30 | 1998-08-27 | 帝国臓器製薬株式会社 | Gelatin capsule |
EP0672414B1 (en) * | 1994-03-15 | 2005-06-08 | Senju Pharmaceutical Co., Ltd. | Method for stabilizing pranoprofen and stable liquid preparation of pranoprofen |
IT1269583B (en) * | 1994-04-26 | 1997-04-08 | Bayer Italia Spa | PHARMACEUTICAL PREPARATIONS BASED ON A SOLUTION OF KETOPROFENE IN SOFT GELATINE CAPSULES AND METHOD FOR THEIR PRODUCTION |
DE69519340T2 (en) * | 1994-08-05 | 2001-06-21 | Shionogi & Co., Ltd. | Hard gelatin capsules resistant to denaturation and processes for their production |
US5620704A (en) * | 1994-11-07 | 1997-04-15 | Warner-Lambert Company | Process for stabilizing gelatin products |
US7115565B2 (en) * | 2001-01-18 | 2006-10-03 | Pharmacia & Upjohn Company | Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability |
-
2003
- 2003-07-31 WO PCT/US2003/024044 patent/WO2004022032A2/en active Application Filing
- 2003-07-31 AU AU2003257102A patent/AU2003257102A1/en not_active Abandoned
- 2003-07-31 BR BR0313064-9A patent/BR0313064A/en not_active IP Right Cessation
- 2003-07-31 WO PCT/US2003/024042 patent/WO2004010972A2/en not_active Application Discontinuation
- 2003-07-31 MX MXPA05001166A patent/MXPA05001166A/en unknown
- 2003-07-31 CA CA002494069A patent/CA2494069A1/en not_active Abandoned
- 2003-07-31 BR BR0312875-0A patent/BR0312875A/en not_active IP Right Cessation
- 2003-07-31 EP EP03794452A patent/EP1526847A2/en not_active Withdrawn
- 2003-07-31 MX MXPA05001272A patent/MXPA05001272A/en unknown
- 2003-07-31 CA CA002494358A patent/CA2494358A1/en not_active Abandoned
- 2003-07-31 BR BR0313150-5A patent/BR0313150A/en not_active IP Right Cessation
- 2003-07-31 AU AU2003257982A patent/AU2003257982A1/en not_active Abandoned
- 2003-07-31 MX MXPA05001167A patent/MXPA05001167A/en unknown
- 2003-07-31 JP JP2004534259A patent/JP2006500389A/en not_active Withdrawn
- 2003-07-31 JP JP2004524263A patent/JP2005538102A/en not_active Abandoned
- 2003-07-31 CA CA002493974A patent/CA2493974A1/en not_active Abandoned
- 2003-07-31 AU AU2003257981A patent/AU2003257981A1/en not_active Abandoned
- 2003-07-31 JP JP2004524261A patent/JP2005538993A/en not_active Withdrawn
- 2003-07-31 CA CA002493980A patent/CA2493980A1/en not_active Abandoned
- 2003-07-31 WO PCT/US2003/024045 patent/WO2004010974A2/en active Application Filing
- 2003-07-31 WO PCT/US2003/024043 patent/WO2004010973A2/en active Application Filing
- 2003-07-31 EP EP03772160A patent/EP1526845A2/en not_active Withdrawn
- 2003-07-31 JP JP2004524262A patent/JP2005538994A/en not_active Withdrawn
- 2003-07-31 EP EP03772159A patent/EP1526844A2/en not_active Withdrawn
- 2003-07-31 EP EP03772161A patent/EP1526846A2/en not_active Withdrawn
- 2003-07-31 MX MXPA05000862A patent/MXPA05000862A/en not_active Application Discontinuation
- 2003-07-31 AU AU2003257103A patent/AU2003257103A1/en not_active Abandoned
- 2003-07-31 BR BR0313149-1A patent/BR0313149A/en not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0315296A (en) | Spirocyclic cyclohexanol derivatives | |
BR0314814A (en) | Optimized variants of fc and methods for their generation | |
BR0307529A (en) | N-phenyl-2-pyrimidine amine derivatives | |
BR0302369A (en) | Assembly elements for assembly structures | |
BR0308339A (en) | Indazoles Replaced with Anticancer Activity | |
GT199900102A (en) | PHENOXIPROPANOLAMINES, PROCEDURE FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM. | |
ES2184408T3 (en) | TRANSDERMAL SYSTEM CONTAINING AN ANTIOXIDANT. | |
BR0215493A (en) | Process for the preparation of scopic esters | |
NO20092274L (en) | Ansamycin formulations and methods of use thereof | |
BR0114410A (en) | Combination of a cb1 receptor antagonist and sibutramine, the pharmaceutical compositions containing them and their use for the treatment of obesity | |
HUP0500084A2 (en) | Encapsulation by coating with a mixture of lipids and hydrophobic, high melting point compounds | |
BR0300709A (en) | Perindopril salt and pharmaceutical compositions containing the same | |
PT1506185E (en) | NEW COMPOUNDS AND THEIR UTILIZATION | |
BRPI0414809A (en) | substituted naphthyl benzothiophene acids | |
BR0318278A (en) | aminocyclohexyl ether compounds and uses thereof | |
BR0311242A (en) | Process for preparing modafinil | |
BRPI0603197A (en) | toner composition | |
BR0313150A (en) | Gelatin capsules exhibiting reduced cross-linking | |
BR0314058A (en) | Branched Alcohol Personal Care Compositions | |
ATE490273T1 (en) | GELATIN CAPSULES | |
BRPI0408848A (en) | oral cladribine formulations | |
AR002017A1 (en) | DERIVATIVES OF FENIL-4-TIAZOLES SUBSTITUTED, PROCEDURE FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND DERIVATIVES DEFENIL-4-TIAZOLES SUBSTITUTED USED IN SUCH PROCEDURE. | |
BR9812085A (en) | "method for the synthesis of quinoline derivatives" | |
PT1017681E (en) | PHARMACEUTICAL AND INTERMEDIATE COMPOUNDS | |
BR0211223A (en) | Substituted 4-aminocyclohexanol derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application fees: dismissal - article 86 of industrial property law |
Free format text: REFERENTE A 6A E 7A ANUIDADE(S). |
|
B08K | Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87) |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2064 DE 27/07/2010. |